Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Ashley L ColeShelley A JazowskiStacie B DusetzinaPublished in: Pharmacoepidemiology and drug safety (2019)
Patients initiating generic imatinib achieved clinically significant improvements in adherence to TKI therapy relative to branded drug users, presumably due to lower out-of-pocket costs. Given the importance of optimal adherence in CML, considering barriers to adherence (eg, patient-cost sharing and health benefit design) when selecting initial treatment may improve long-term medication adherence. Pharmacoepidemiologic studies should consider how best to account for expected cost-sharing and its impact on adherence and subsequent clinical outcomes.
Keyphrases
- chronic myeloid leukemia
- health information
- end stage renal disease
- healthcare
- glycemic control
- ejection fraction
- social media
- public health
- newly diagnosed
- mental health
- prognostic factors
- type diabetes
- case report
- adipose tissue
- stem cells
- tyrosine kinase
- emergency department
- mesenchymal stem cells
- replacement therapy
- skeletal muscle
- weight loss